Jeonjinbio Co. Ltd (110020) — Cash Flow-to-Debt Ratio
Jeonjinbio Co. Ltd (110020) has a Cash Flow-to-Debt Ratio of 0.25x as of September 2025, meaning its operating cash flow of ₩313.21 Million could theoretically repay 0% of its total liabilities (₩1.27 Billion) in one year. See 110020 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jeonjinbio Co. Ltd Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Jeonjinbio Co. Ltd across 10 annual periods. Also explore Jeonjinbio Co. Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Jeonjinbio Co. Ltd (2015–2024)
Year-by-year debt coverage analysis for Jeonjinbio Co. Ltd. For market capitalisation and broader financial context, see Jeonjinbio Co. Ltd market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 2.52x | ₩3.01 Billion | ₩1.19 Billion | ▲ +9732.7% |
| 2023 | -0.03x | ₩-300.60 Million | ₩11.48 Billion | ▲ +94.1% |
| 2022 | -0.44x | ₩-3.71 Billion | ₩8.36 Billion | ▼ -161.0% |
| 2021 | -0.17x | ₩-2.38 Billion | ₩14.02 Billion | ▲ +45.4% |
| 2020 | -0.31x | ₩-2.31 Billion | ₩7.41 Billion | ▲ +15.7% |
| 2019 | -0.37x | ₩-1.30 Billion | ₩3.51 Billion | ▲ +45.1% |
| 2018 | -0.67x | ₩-2.16 Billion | ₩3.21 Billion | ▼ -523.8% |
| 2017 | -0.11x | ₩-413.19 Million | ₩3.83 Billion | ▼ -110.6% |
| 2016 | -0.05x | ₩-181.90 Million | ₩3.55 Billion | ▲ +79.1% |
| 2015 | -0.25x | ₩-1.95 Billion | ₩7.95 Billion | — |